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This special issue, “Monoamine oxidase (MAO) and aggression”, considers the 
evidence linking the monoaminergic neurotransmitters as regulated by the breakdown 
enzymes MAO A and B, and aggressive behavior.  Encoded by separate genes on the 
X chromosome, MAO A and B both catalyze the breakdown of amines but have 
different catalytic properties and distinctly different distribution across the brain.  
 
By way of introduction, Ramsay (2016) has reviewed the molecular aspects of MAO, 
focusing particularly on the B form of MAO (MAO B). MAO B is constitutively 
expressed throughout the body but is the predominant form in platelets and glial cells. 
Lower MAO activity means higher amine levels and vice versa as established by 
urinary and post-mortem measurements, or by microdialysis in rats.  A brief 
description of the classic work on MAO expression is updated with recent 
observations of epigenetic regulation of MAO activity. MAO inhibition raises brain 
amine levels, a fact exploited for antidepressant effect, and now being incorporated 
into multi-target compounds to combat neurodegenerative conditions. Catalysis, 
mechanism and inhibition of MAO, important both for measuring levels in tissues and 
for drug design, are described. Of the successful irreversible drugs that inhibit MAO 
B, the classic non-selective MAO inhibitor, phenelzine, the MAO B-selective 
inhibitor deprenyl (selegiline, now commonly used in PD), and the cyclopropylamine, 
Parnate, are highlighted, along with labazemide as a reversible inhibitor. Recent 
developments in reversible inhibitor design include some compounds with nanomolar 
affinity but there is no indication that they will be successful in vivo. In the meantime, 
the traditional irreversible inhibitors are effective and well understood drugs. 
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Behavioral links with MAO activity have been greatly advanced by recent 
translational work informed by transgenic mice. In their article, Godar and colleagues 
(Godar et al., 2016) review the role of monoamine oxidase A (MAOA) in the 
ontogeny of aggression. The first discovery of a connection between the MAOA gene 
and antisocial behavior came from the identification of a rare null-allele mutation and 
high propensity for violent crimes in the males of a Dutch family. Following this 
finding, several investigations have identified that aggression propensity is influenced 
by a functional VNTR (variable number of tandem repeats) polymorphism of the 
promoter of this gene; in particular, numerous independent studies have shown that 
low-activity VNTR alleles may interact with child abuse and/or neglect to facilitate 
the development of aggressive traits in adolescence and adulthood. In addition, 
several brain-imaging studies have identified that MAOA low-activity alleles are 
associated with alterations of cortico-amygdalar connectivity. The neurobiological 
underpinnings of these phenomena, however, remain poorly understood. A promising 
tool to investigate these issues is afforded by animal models, most notably mice 
harboring hypomorphic mutations of Maoa. Phenotypical analyses of these transgenic 
animals have revealed numerous elements of convergence with human data; in 
particular, Godar et al. show how the integration of animal and human studies is 
likely to refine our current understanding of the neurodevelopmental mechanisms of 
aggression, and assist in the development of novel therapies. 
 
Harro and Oreland (2016) cover the history and state of the art of the studies 
describing the links between MAO and personality, with focus on alcohol abuse.  
Both MAO-A and MAO-B have been implicated in shaping personality and 
regulation of behavior, but their stories differ with regard to how either of the 
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isoenzymes came to the research limelight, what has most frequently been measured, 
what has been found and what their roles appear to be. While most of the studies are 
consistent in associating both MAO-A and MAO-B with impulsive, aggressive or 
antisocial personality traits or behavior, there are notable exceptions, and attempts to 
explain these divergent findings has provided insights into the salience of 
developmental aspects and gender roles. Adverse environmental factors, especially in 
childhood, strongly interact with the MAO measures in predicting future behavior but, 
importantly, the "risk variants" seem to increase not simply vulnerability but 
plasticity, hence being advantageous in supportive environments. Nevertheless, there 
is little evidence that variation in MAO activity in adulthood is the source of variation 
in the brain plasticity; indeed, it may be that the time window is already in the fetal 
period when monoamine neurotransmitters elicit their neurotrophic effects and serve 
as a source of differences in brain structure and functional connectivity. A possibility 
to look into this early period is provided by the only isoenzyme present in platelets 
(MAO-B) that remains uninfluenced by the epigenetic effects of life events on the 
brain and may inform on the enzyme activity during early development. While the 
location of the MAO genes on the X chromosome obviously contributes to at least 
some of the sex differences found in gene-environment interactions, the gender roles 
may act as hitherto unrecognized significant mediators that lead to the remarkably 
different findings in males and females (Harro and Oreland 2016).  
 
The review by Fisar (2016) describes drugs use to inhibit monoamine oxidase 
activity, the role of monoamine neurotransmission in neuropsychiatric disorders with 
connection to MAO activity, and the therapeutic role of MAO inhibitors. The paper 
focuses on regulation of monoaminergic neurotransmission by the drug-induced 
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regulation of MAO, including recent developments showing that some drugs function 
both as inhibitors of MAO activity and as modulators of gene expression. The 
association between the disturbances in monoamine systems and MAO activity with 
the pathogenesis of depressive disorder, schizophrenia, bipolar disorder, drug 
addiction, pathological aggression and Parkinson’s and Alzheimer’s diseases is 
described. Finally, new hybrid drugs that inhibit MAO or other mitochondrial 
enzymes are introduced to cover the latest developments for the treatment of the latter 
degenerative disorders. (Fisar, 2016).  
 
The Borovecki group review (Gotovac et al., 2016) describes recent data on the 
biomarkers of aggression in dementia. This review focuses on the current literature 
regarding neuropsychiatric symptoms, especially agitation and aggressive behavior in 
dementia. Since the rate of aggression correlates with loss of independence, cognitive 
decline and poor outcome in patients with dementia, search for neurobiological, 
neurochemical, and genetic biomarkers of these behaviors might provide better 
understanding of their etiological background. The genetic markers described include 
genes encoding components of the serotonin system (for tryptophan hydroxylase, 
serotonin transporter and 5-HT2A receptor gene), apolipoprotein E (APOE), 
dopamine receptor, MAO-A and MAO-B, and genetic loci in the serine/threonine 
kinase 11 (STK11) and visinin-like 1 (VSNL1) genes. Neurotransmitter biomarkers 
associated with aggression in dementia are related to parts of the dopamine, 
norepinephrine, acetylcholine, glutamate, serotonin, and GABA systems. 
Neuropathological changes in aggression include increased atrophy in frontal and 
cingulated cortices, amygdala, hippocampus and insula. Some CST biomarkers such 
as increased levels of P-tau and T-tau were associated with apathy, while a negative 
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correlation was found between the levels of CSF Aβ1-42 and increased aggressive 
behavior. Management of aggression and agitation includes pharmacological (off 
label use of atypical antipsychotics; promising new drugs in the Phase II and III trials  
- brexpiprazole (dopamine D2 receptor partial agonist) and mibampator, 
dextromethorphan/quinidine, cannabinoids, and citalopram) and non-pharmacological 
(sensory, psychological and behavioral) treatments (Gotovac et al., 2016). 
 
In the only research article in this special issue, Pivac’s group (Nikolac Perkovic et 
al., 2016) presented their clinical data on MAO and agitation in psychiatric patients. 
The authors aimed to evaluate the possible association of either the activity or 
genetics of MAO (i.e platelet MAO-B activity, and two polymorphisms related to 
MAO-B and MAO-A genes: MAOB rs1799836 polymorphism and MAOA-uVNTR 
polymorphism) with severe agitation in psychiatric patients. Some hypotheses 
associate agitation and high aggression in psychiatric patients with reduced platelet 
MAO-B activity, and with the more frequent presence of the low (3-repeat; 3R) 
activity variants of the MAOA uVNTR polymorphism. This study included 363 
subjects with schizophrenia and conduct disorder. Agitation was selected as a 
construct of pathological behavior (in line with Research Domain Criteria, RDoC) 
present in different psychiatric disorders. Severe agitation was significantly associated 
with smoking and with platelet MAO-B activity. Nikolac Perkovic et al. (2016) 
suggested that platelet MAO-B activity might be useful in differentiating subjects 
with or without severe agitation. On the other hand, in contrast to their hypothesis, 
severe agitation was not associated with MAOA-uVNTR or MAOB rs1799836 
polymorphism, nor did these data show any association between the individual MAOB 
rs1799836 and MAOA uVNTR variants and severe agitation in subjects with 
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schizophrenia and conduct disorder. The authors concluded that agitation, which 
develops in many psychiatric disorders, has complicated etiology. Monoaminergic 
imbalance, together with deficits in other neurotransmitter systems, complicated with 
the interactions with different environmental and developmental factors, may 
contribute to the expression of agitation (Nikolac Perkovic et al., 2016). 
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